Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Artelo Biosciences Q3 2026 Results: Net Loss of $1.77M, Loss Narrows

Artelo Biosciences reported a net loss of $7.15 million for the nine months ended September 30, 2026, compared to $8.71 million in the prior year period. The company strengthened its balance sheet through equity financing, ending the quarter with $4.44 million in cash and cash equivalents, up from $0.6 million at the start of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.8-3.1
EPS (diluted, $ a share)$-3.19$-88.80

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ARTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Artelo Biosciences, Inc.: key numbers

Share price
$1.70Close, Nov 16
Market cap
$1.59M
Shares outstanding
937.18KLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Artelo Biosciences, Inc.

All →
5:16 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Artelo Biosciences Nasdaq/NYSE Compliance Notice

Artelo Biosciences was identified as one of approximately 180 companies currently below Nasdaq's new $5 million minimum Market Value of Listed Securities (MVLS) requirement. While the rule is currently under a temporary stay and subject to proposed modifications, the company is monitoring the situation and considering potential actions to maintain compliance, such as capital raises or expense management.

Counterparty
Nasdaq

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.